Evaluation of overexpression of VEGF-C mRNA of extrahepatic bile duct carcinoma using surgical and endoscopic samples obtained with biopsy or brushing cytology during endoscopic retrograde cholangiopancreatography

Evaluation of overexpression of VEGF-C mRNA of extrahepatic bile duct carcinoma using surgical and endoscopic samples obtained with biopsy or brushing cytology during endoscopic retrograde cholangiopancreatography - The expression of VEGF-C mRNA of extrahepatic bile duct cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007092

Enrollment

Registered

2012-01-17

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extrahepatic bile duct cancer

Interventions

Evaluation of VEGF-C mRNA and protein

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The patients who are suspected of extrahepatic bile duct cancer and have a plan to take the examination of ERCP. 2.Performance status; 0,1,2

Exclusion criteria

Exclusion criteria: 1.The patients who take anticoagulants 2.The patients with acute pancreatitis 3.The patient who have already take chemotherapy or radiotherapy 4.The patients who are pregnant

Design outcomes

Primary

Measure	Time frame
Evaluation of VEGF-C of extrahepatic bile duct cancer using surgical and endoscopic samples	—

Secondary

Measure	Time frame
The expression of VEGFR-3,lymphovascular invasion, lymph node metastasis	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026